Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2020 - 2026)

Neurocrine Biosciences filings provide 7 years of Long-Term Deferred Tax readings, the most recent being $320.3 million for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax fell 34.05% to $320.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $320.3 million, a 34.05% decrease, with the full-year FY2025 number at $320.3 million, down 34.05% from a year prior.
  • Long-Term Deferred Tax hit $320.3 million in Q4 2025 for Neurocrine Biosciences, down from $368.5 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $536.8 million in Q2 2025 to a low of $305.9 million in Q4 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $350.0 million (2023), compared with a mean of $373.6 million.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 33.95% in 2024 and later crashed 34.05% in 2025.
  • Neurocrine Biosciences' Long-Term Deferred Tax stood at $315.1 million in 2021, then decreased by 2.92% to $305.9 million in 2022, then grew by 18.54% to $362.6 million in 2023, then soared by 33.95% to $485.7 million in 2024, then crashed by 34.05% to $320.3 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $320.3 million (Q4 2025), $368.5 million (Q3 2025), and $536.8 million (Q2 2025) per Business Quant data.